CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 1,110,000 shares, an increase of 63.5% from the September 30th total of 679,000 shares. Based on an average daily volume of 13,620,000 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Inflows and Outflows
An institutional investor recently raised its position in CNS Pharmaceuticals stock. Virtu Financial LLC increased its position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Free Report) by 616.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent quarter. 14.02% of the stock is owned by institutional investors.
CNS Pharmaceuticals Stock Performance
Shares of NASDAQ:CNSP opened at $0.13 on Friday. The company has a market cap of $190,764.60, a PE ratio of 0.00 and a beta of 2.57. CNS Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $137.50. The firm has a 50 day simple moving average of $0.14 and a 200 day simple moving average of $3.62.
Wall Street Analysts Forecast Growth
Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Tuesday, September 10th.
View Our Latest Stock Analysis on CNSP
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
Featured Articles
- Five stocks we like better than CNS Pharmaceuticals
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Nasdaq? Complete Overview with History
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.